The ABLIM1 Knockout SK-HEP-1 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human SK-HEP-1 cell line, featuring targeted disruption of the ABLIM1 gene. This polyclonal population comprises a heterogeneous mixture of cells with ABLIM1 gene disruption, creating a loss-of-function model for studying ABLIM1 in hepatocellular carcinoma. The ABLIM1 gene encodes an actin-binding LIM protein, and its knockout in the SK-HEP-1 liver adenocarcinoma cell line enables investigation of its roles in cytoskeletal organization and cell adhesion. The polyclonal format avoids clonal selection, offering a representative population for functional and phenotypic assays.
The SK-HEP-1 host cell line is a human liver adenocarcinoma cell line with a mixed endothelial and epithelial phenotype. It is widely employed for studying hepatocellular carcinoma progression, metastasis, and the endothelial-like characteristics that contribute to tumor angiogenesis and dissemination. This dual phenotype makes SK-HEP-1 an ideal model for examining the interplay between cell adhesion, cytoskeletal dynamics, and signaling pathways governing cancer cell motility.
ABLIM1 encodes an actin-binding LIM domain protein that scaffolds the actin cytoskeleton to cell adhesion complexes. It interacts with F-actin and beta-catenin, integrating Wnt/beta-catenin and TGF-beta signaling to regulate cytoskeletal remodeling and adhesion. ABLIM1 expression is transcriptionally controlled by beta-catenin/TCF, and it modulates actin filament organization, focal adhesions, and cell-cell junctions involving E-cadherin and integrins. Thus, ABLIM1 coordinates cell morphology, adhesion, and migration.
In the SK-HEP-1 hepatocellular carcinoma background, ABLIM1 knockout disrupts the actin-binding LIM protein function, leading to impaired cytoskeletal organization and altered cell adhesion. This loss-of-function model is predicted to alter beta-catenin subcellular localization and signaling, consequently affecting downstream pathways that regulate hepatocellular carcinoma cell migration and invasion. The mixed endothelial/epithelial phenotype of SK-HEP-1 cells provides a unique context to study how ABLIM1 influences the balance between epithelial stability and mesenchymal motile properties, relevant to cancer metastasis. Thus, these knockout cells serve as a powerful tool to dissect the mechanistic role of ABLIM1 in liver cancer progression.
Researchers can employ the ABLIM1 Knockout SK-HEP-1 Polyclonal Cells in a variety of assays to probe the molecular mechanisms of hepatocellular carcinoma. Typical applications include western blotting and immunofluorescence to assess changes in cytoskeletal and adhesion proteins, as well as functional assays such as cell migration, invasion, and adhesion assays to quantify metastatic potential. Additionally, RT-qPCR and beta-catenin reporter assays can be used to monitor Wnt signaling pathway activity. These polyclonal knockout cells are suitable for drug screening studies targeting HCC cell motility and for investigating cytoskeletal remodeling in an endothelial-like context. For more information, please contact Ascent Research.
